Product Images Oxcarbazepine

Not available.*

This is a study on the efficacy of Oxcarbazepine compared to Placebo in preventing seizures. The data shows a significant difference between the two groups, with Oxcarbazepine being more effective in reducing seizures. The p-value obtained from log-rank test is 0.046. The x-axis represents the number of days from the first dose while the y-axis represents the number of seizures.*

The text describes the medication Oxcarbazepine in tablet form with a strength of 300mg. It includes instructions for storage, warnings against the use for children as this particular packaging is not child-resistant, and information about the manufacturer and distributor. The usual dosage is not provided and the buyer is advised to see the product insert for full prescribing information, precautions, and warnings. The package comes in a unit dose that is intended for institutional use only but should be dispensed for outpatient use in a child-resistant container. The drug product contained in the package is from Breckenridge Pharmaceutical, Inc.*

This is a pack of OXCARBAZEPINE TABLETS, USP containing 10 tablets each with a strength of 150 mg. It is intended for institutional use only and contains FD&C Yellow No. 5 as a color additive. The package has warnings regarding child-resistant packaging, and it should not be used if the blister is torn or broken. The usual dosage information can be found on the product insert, along with prescribing information, precautions, and warnings. It should be stored at a temperature of between 20° and 25° C (68° to 77° F), with excursions permitted between 15° to 30° C (59° to 86° F). The drug product is from NDC # 51991-292, Breckenridge Pharmaceutical, Inc., and it is distributed by American Health Packaging, Columbus, OH 43217, and Cardinal Health, Dublin, OH 43017.*